BFM
IMVT icon

Boothbay Fund Management’s Immunovant IMVT Stock Holding History

Boothbay Fund Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-91,800
Closed -$2.27M – 1574
2024
Q4 		$2.27M Sell
91,800
-58,400
-39% -$1.66M 0.06% 415
2024
Q3 		$4.28M Buy
150,200
+123,700
+467% +$3.65M 0.1% 296
2024
Q2 		$700K Buy
+26,500
New +$754K 0.02% 873
2024
Q1 		– Sell
-71,500
Closed -$3.01M – 1741
2023
Q4 		$3.01M Sell
71,500
-75,300
-51% -$2.77M 0.08% 361
2023
Q3 		$5.64M Buy
146,800
+80,900
+123% +$1.83M 0.13% 186
2023
Q2 		$1.25M Buy
65,900
+33,800
+105% +$630K 0.03% 742
2023
Q1 		$498K Buy
+32,100
New +$557K 0.01% 1257
2021
Q3 		– Sell
-45,300
Closed -$479K – 2036
2021
Q2 		$479K Buy
45,300
+44,897
+11,141% +$627K 0.02% 1024
2021
Q1 		$646K Buy
+403
New +$10.6K 0.02% 807

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Boothbay Fund Management's IMVT Position: Q3 2024 in Review

Boothbay Fund Management sold out of Immunovant (IMVT) in Q3 2024, closing a stake of 64,796 shares — an estimated $1.91M sold.

Boothbay Fund Management first reported a position in IMVT in Q3 2019 and held it in 15 quarters. The position peaked at $4.33M in Q3 2019. 181 funds tracked by Wall St. Rank hold IMVT as of Q3 2024.

  • Boothbay Fund Management reported no remaining Immunovant position as of Q3 2024 after selling out during the quarter.
  • Boothbay Fund Management sold 64,796 Immunovant shares in Q3 2024, an estimated $1.91M.
  • Boothbay Fund Management first reported a position in Immunovant in Q3 2019 and held it in 15 quarters.
  • Boothbay Fund Management's Immunovant position peaked at $4.33M in Q3 2019.
  • 181 funds tracked by Wall St. Rank held Immunovant as of Q3 2024.

Based on Boothbay Fund Management's 13F filing for Q3 2024, filed 14 Nov 2024.